Spectral Announces Status of Second Interim Analysis
News Jan 31, 2014
Spectral Diagnostics Inc. has announced that the Data Safety Monitoring Board (DSMB) has evaluated the safety, efficacy and futility of its EUPHRATES trial based on actual data for 184 randomized patients followed for 28 days.
The DSMB has recommended that the trial continue, but has asked that further analysis be performed before recalculation of the trial's sample size is finalized.
"The Company will await the specifics of the DSMB report, expected soon, before determining next steps in its clinical and commercial pathway," said Dr. Paul Walker, President and CEO of Spectral Diagnostics.
Protein Discovery Could Lead to Better Diagnosis of StressNews
Researchers have found a protein that is present in people while they are in stressful situations. The discovery could lead to identifying new ways to predict, diagnose and treat stress.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE